TY - JOUR T1 - CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 6107 LP - 6111 DO - 10.21873/anticanres.12961 VL - 38 IS - 11 AU - KEISUKE KUHARA AU - KAZUHIRO TOKUDA AU - TAKAO KITAGAWA AU - BYRON BARON AU - MASAYUKI TOKUNAGA AU - KOJI HARADA AU - MASARU TERASAKI AU - OSAMU UEHARA AU - TOHRU OHTA AU - RIE TAKAI AU - JUN-ICHI HAMADA AU - MASANOBU KOBAYASHI AU - TSUYOSHI SHIMO AU - HIROKI NAGAYASU AU - YASUHIRO KURAMITSU Y1 - 2018/11/01 UR - http://ar.iiarjournals.org/content/38/11/6107.abstract N2 - Background/Aim: We have previously reported that treatment of pancreatic cancer cells with active hexose-correlated compound (AHCC), an extract of a basidiomycete mushroom, decreases the levels of tumor-associated proteins including heat-shock protein 27 (HSP27), heat shock factor 1 (HSF1) and sex-determining region Y-box 2 (SOX2). The transmembrane glycoprotein, CUB domain-containing protein 1 (CDCP1) has been reported to be up-regulated in various cancers, and be associated with invasion and metastasis. The aim of this study was to examine the effect of AHCC on the expression of CDCP1 in KLM1-R cells. Materials and Methods: Gemcitabine-resistant pancreatic cancer cells (KLM1-R) were treated with AHCC (10 mg/ml) for 48 h. Western blot analysis of cell extracts with anti-CDCP1 or anti-actin antibodies was performed to assess the expression of CDCP1. Results: Expression of CDCP1 was reduced by AHCC treatment of KLM1-R cells, whereas expression of actin was not affected. The ratio of intensities of CDCP1/actin in AHCC-treated KLM1-R cells was significantly suppressed (p<0.05) compared to untreated cells. Conclusion: AHCC down-regulated CDCP1 expression and inhibited the malignant progression of pancreatic cancer cells. ER -